Literature DB >> 12932074

HIV-1 entry and its inhibition.

T C Pierson1, R W Doms.   

Abstract

Entry of HIV-1 virions into cells is a complex and dynamic process carried out by envelope (Env) glycoproteins on the surface of the virion that promote the thermodynamically unfavorable fusion of highly stable viral and target cell membranes. Insight gained from studies of the mechanism of viral entry allowed insight into the design of novel inhibitors of HIV-1 entry, several of which are now in clinical trials. This review highlights the mechanism by which viral and cellular proteins mediate entry of HIV-1 into permissive cells, with an emphasis on targeting this process in the design of novel therapies that target distinct steps of the entry process, including antagonizing receptor binding events and blocking conformational changes intimately involved in membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932074     DOI: 10.1007/978-3-642-19012-4_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  42 in total

Review 1.  Dangerous liaisons at the virological synapse.

Authors:  Vincent Piguet; Quentin Sattentau
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

2.  Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Authors:  Chan-Sien Lay; Louise E Ludlow; David Stapleton; Anna K Bellamy-McIntyre; Paul A Ramsland; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

3.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Authors:  Manish Sagar; Xueling Wu; Sandra Lee; Julie Overbaugh
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.

Authors:  Simon Cocklin; Hosahudya Gopi; Bianca Querido; Manideepthi Nimmagadda; Syna Kuriakose; Claudia Cicala; Sandya Ajith; Sabine Baxter; James Arthos; Julio Martín-García; Irwin M Chaiken
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay.

Authors:  Suzanne Pontow; Brooke Harmon; Nancy Campbell; Lee Ratner
Journal:  Virology       Date:  2007-07-19       Impact factor: 3.616

8.  Nanofilaments on glioblastoma exosomes revealed by peak force microscopy.

Authors:  Shivani Sharma; Kingshuk Das; JungReem Woo; James K Gimzewski
Journal:  J R Soc Interface       Date:  2014-01-08       Impact factor: 4.118

9.  Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Ann Cheung; James R Perry; Darrick Carter; Steve Reed; Hanneke Schuitemaker; Maria Grazia Pau; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  Vaccine       Date:  2014-02-18       Impact factor: 3.641

10.  An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.

Authors:  Brian M Taylor; J Scott Foulke; Robin Flinko; Alonso Heredia; Anthony DeVico; Marvin Reitz
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.